Revolade approved for use in hepatitis C therapyRevolade, a platelet-boosting drug marketed by GlaxoSmithKline (GSK), has achieved EU approval. The drug treats patients whose low blood platelet count is adversely affecting the work of therapies to fight the hepatitis C virus.

New comprehensive all-oral regimens would impact upon the need for Revolade but GSK believe the drug can still strongly benefit patients using the drug with low platelet counts.

Read our article on Revolade here:



Add a comment

Your email address will not be published. Required fields are marked *